Objective:

To explore the role of collagen in dry eye disease and the therapeutic potential of collagen mimetic peptides, emphasizing its significance in ocular health.

Key Findings:

• Collagen is essential for corneal epithelial integrity and function, impacting patient quality of life.
• Dry eye disease leads to collagen fragmentation, exacerbating inflammation and epithelial damage, necessitating targeted therapies.
• Superficial punctate keratitis disrupts visual quality and complicates corneal measurements, affecting patient outcomes.
• Collagen mimetic peptides can selectively repair damaged collagen and restore epithelial function, offering a new treatment avenue.
• The ST-100 trial showed significant clinical improvements in corneal staining, indicating potential for broader application.

Interpretation:

Collagen plays a critical role in maintaining corneal health, and its disruption in dry eye disease highlights the potential of collagen mimetic therapies to restore ocular surface integrity.

Limitations:

• Further studies are needed to fully understand the long-term effects of collagen mimetic therapies, particularly in diverse populations.
• The generalizability of trial results may be limited by sample size and study design, highlighting the need for larger, multi-center trials.

Conclusion:

Collagen mimetic peptides represent a promising therapeutic approach for managing dry eye disease by targeting the underlying collagen damage, which is critical for restoring ocular surface integrity.